As of 2:31 PM on the 24th, Medytox is trading at 181,400 KRW, down 3.36% from the previous day. The trading volume is 382,367 shares, which is about 30.32% of the previous day's volume. Medytox is known as a manufacturer and seller of pharmaceuticals and cosmetic pharmaceuticals.
On February 22, Hana Financial Investment researcher Sun Min-jung announced, "As of February 19, U.S. time, Medytox, Allergan, and Evolus have reached a sudden settlement regarding the ITC lawsuit and intellectual property lawsuit that imposed a 21-month sales ban on Nabota in the U.S. As a result, Evolus will be able to sell Nabota in the U.S., and the lawsuit filed by Medytox against Evolus in California will be withdrawn. Contracts are segmented between the U.S. and the rest of the world (ROW). With this settlement with Evolus, Medytox is expected to gain significant practical benefits." She set Medytox's target price at 430,000 KRW.
Over the past five days, individual investors have net sold 17,204 shares of Medytox, while foreigners and institutions have net sold 13,969 shares and net bought 30,581 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
